PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1383328
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1383328
Fibrocystic Breasts Diagnostics and Treatment Market Forecasts to 2030 - Global Analysis By Type (Breast Biopsy, Nonsteroidal Anti Inflammatory Drugs, Acetaminophen, Oral Contraceptives and Other Types) End User and By Geography
According to Stratistics MRC, the Global Fibrocystic Breasts Diagnostics and Treatment Market is expected to grow at a CAGR of 9.9% during the forecast period. The healthcare industry's response to fibrocystic breast disease, a common benign breast disorder in which the breast tissue becomes lumpy, sensitive, and sometimes painful, is embraced by the fibrocystic breasts diagnostics and treatment market. The growth of noncancerous breast lumps and related discomfort are symptoms of fibrocystic breasts, a common illness. Mammograms, ultrasounds, and occasionally biopsies are used as part of diagnostic procedures for breast cancer. The aim of treatment is symptom control, which may entail dietary adjustments, medications for pain, and supportive bras.
According to the American Cancer Society's evaluations, there are chances of around 266,120 new cases of breast cancer may be identified only in 2018 and about 40,920 women may die due to breast cancer.
Market Dynamics:
Driver:
Rise of fibrocystic breasts in women
The factors that rise the market growth are high incidence of fibrocystic breasts in women, which is thought to affect a significant portion of the female population, generates significant demand for diagnostic resources and treatments, which attracts the attention of healthcare professionals, pharmaceutical firms, and manufacturers of medical equipment. Additionally, the invention and adoption of new diagnostic and treatment options in this industry are supported by rising healthcare spending by both individuals and governments.
Restraint:
High cost
While new diagnostic and therapeutic options have the potential to improve patient care, they frequently have a high cost, making them less readily available to a larger population. As a result, there may be hurdles to early and efficient diagnosis and treatment for people with limited financial resources or inadequate insurance coverage. However, this can result in inequities and inequalities in healthcare. Accessibility may also be further constrained by the uneven geographic distribution of specialized healthcare facilities and competent individuals, particularly in rural or underdeveloped areas.
Opportunity:
Technological developments
The accuracy of fibrocystic breast diagnoses has increased due to developments in medical imaging technology, including 3D mammography and high-resolution ultrasounds. Digital health tools and advancements in biopsy methods also improve diagnostic capabilities. Moreover, the way fibrocystic breast disease is detected, tracked, and treated has undergone a radical change because of developments in medical technology. Modern imaging technologies like digital mammography and 3D tomo synthesis offer improved precision and early detection, minimizing false positives and unnecessary operations. Technology has made it possible to do accurate tissue sampling with less invasive biopsy methods, reducing patient suffering.
Threat:
Targeted therapies are limited
There is a lack of accurate, focused therapy for fibrocystic breast disease despite advances in technology. Rather than focusing on the root causes, treatments mostly manage symptoms. The availability of targeted medicines, which are intended to specifically tackle the molecular or genetic components causing the illness, is slightly restricted. However, the difficulty in developing accurate and efficient targeted treatments for fibrocystic breast disease can be due to the absence of a thorough understanding of the precise etiology of the condition.
COVID-19 Impact:
Routine mammograms and breast examinations were among the non-urgent medical procedures and screenings that had to be delayed or canceled during the peak of the pandemic in order to make space for COVID-19 patients. In certain instances, this delay in screenings may have hampered the timely identification and diagnosis of fibrocystic breasts. Clinical trials and current research across several medical specialties were affected by the pandemic. Studies looking at novel diagnostic techniques or therapy options for fibrocystic breasts may have been hindered by this delay.
The breast biopsy segment is expected to be the largest during the forecast period
Breast Biopsy segment dominated the largest share over the forecast period. Breast biopsies are becoming more popular as a result of increased awareness and emphasis on early detection, as they provide a reliable way to confirm the presence of fibrocystic alterations and distinguish them from malignancies. Furthermore, the precise diagnosis of fibrocystic breast disease and the elimination of potentially malignant growths depend heavily on biopsy procedures. This part covers numerous biopsy methods that can be used to get the required tissue samples for pathological analysis, including vacuum-assisted, core needle, and fine needle aspiration.
The hospitals segment is expected to have the highest CAGR during the forecast period
The hospital category is anticipated to have the highest CAGR throughout the projected period as primary healthcare facilities for diagnosis and treatment are equipped with cutting-edge medical technologies and experience, making them the go-to facilities for entirely managing fibrocystic breast problems. Moreover, for patients' convenience and effectiveness, they frequently provide a variety of diagnostic services under one roof, ranging from clinical breast exams to cutting-edge imaging and biopsy treatments, medical facilities frequently act as referral hubs for complicated cases, attracting patients in need of specialist care such as cutting-edge diagnostic procedures and operations.
Region with largest share:
The Asia Pacific region holds the largest share as a result of the region's improved healthcare infrastructure and growing economic development, which have increased the affordability and accessibility of cutting-edge medical technologies and treatments, making it simpler for patients to access cutting-edge diagnostic and treatment options. Additionally, innovative diagnosis and treatment methods have also been developed as a result of the Asia-Pacific region's active research and development efforts, usually in cooperation with foreign healthcare organizations.
Region with highest CAGR:
Due to the region's huge and varied population, particularly in countries like India and China, which contribute to a substantial number of potential patients, the Asia-Pacific region is expected to have an increase in demand for fibrocystic breast disease diagnostics and treatments over the projected period. Further, due to the growing awareness of breast health and early detection that has been spurred by education programs and simpler access to healthcare. These factors urge more women to seek medical attention and undergo breast exams and tests.
Key players in the market
Some of the key players in Fibrocystic Breasts Diagnostics and Treatment market include: Argon Medical Devices, Boston Scientific, CareFusion Corporation, Cook Medical, INRAD, Inc, Devicor Medical Products Inc, Allergan plc, Bayer AG, Teva Pharmaceutical Industries Ltd, Merck & Co., Inc, Gallini Medical Devices and Pfizer Inc.
Key Developments:
In September 2023, Boston Scientific to buy chronic back pain therapy maker Relievant. Medical devices maker Boston Scientific (BSX.N) would buy private medical tech company Relievant Medsystems for an upfront cash payment of $850 million, gaining access to an FDA-cleared therapy for chronic pain.
In March 2023, Argon Medical introduces Traveler Portal Vein Access Series. TRAVELER has been designed to improve the visualisation and durability of components, helping to address some of the common challenges faced during Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedures.
Types Covered:
- Breast Biopsy
- Nonsteroidal Anti Inflammatory Drugs
- Acetaminophen
- Oral Contraceptives
- Other Types
End Users Covered:
- Diagnostic Centers
- Hospitals
- Research Institutes
- Specialty Clinics and Rehab Centers
- Other End Users
Regions Covered:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 End User Analysis
- 3.7 Emerging Markets
- 3.8 Impact of Covid-19
4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
5 Global Fibrocystic Breasts Diagnostics and Treatment Market, By Type
- 5.1 Introduction
- 5.2 Breast Biopsy
- 5.3 Nonsteroidal Anti Inflammatory Drugs
- 5.4 Acetaminophen
- 5.5 Oral Contraceptives
- 5.6 Other Types
6 Global Fibrocystic Breasts Diagnostics and Treatment Market, By End User
- 6.1 Introduction
- 6.2 Diagnostic Centers
- 6.3 Hospitals
- 6.4 Research Institutes
- 6.5 Specialty Clinics and Rehab Centers
- 6.6 Other End Users
7 Global Fibrocystic Breasts Diagnostics and Treatment Market, By Geography
- 7.1 Introduction
- 7.2 North America
- 7.2.1 US
- 7.2.2 Canada
- 7.2.3 Mexico
- 7.3 Europe
- 7.3.1 Germany
- 7.3.2 UK
- 7.3.3 Italy
- 7.3.4 France
- 7.3.5 Spain
- 7.3.6 Rest of Europe
- 7.4 Asia Pacific
- 7.4.1 Japan
- 7.4.2 China
- 7.4.3 India
- 7.4.4 Australia
- 7.4.5 New Zealand
- 7.4.6 South Korea
- 7.4.7 Rest of Asia Pacific
- 7.5 South America
- 7.5.1 Argentina
- 7.5.2 Brazil
- 7.5.3 Chile
- 7.5.4 Rest of South America
- 7.6 Middle East & Africa
- 7.6.1 Saudi Arabia
- 7.6.2 UAE
- 7.6.3 Qatar
- 7.6.4 South Africa
- 7.6.5 Rest of Middle East & Africa
8 Key Developments
- 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 8.2 Acquisitions & Mergers
- 8.3 New Product Launch
- 8.4 Expansions
- 8.5 Other Key Strategies
9 Company Profiling
- 9.1 Argon Medical Devices
- 9.2 Boston Scientific
- 9.3 CareFusion Corporation
- 9.4 Cook Medical, INRAD, Inc
- 9.5 Devicor Medical Products Inc
- 9.6 Allergan plc
- 9.7 Bayer AG
- 9.8 Teva Pharmaceutical Industries Ltd
- 9.9 Merck & Co., Inc
- 9.10 Gallini Medical Devices
- 9.11 Pfizer Inc
List of Tables
- Table 1 Global Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Region (2021-2030) ($MN)
- Table 2 Global Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Type (2021-2030) ($MN)
- Table 3 Global Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Breast Biopsy (2021-2030) ($MN)
- Table 4 Global Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Nonsteroidal Anti Inflammatory Drugs (2021-2030) ($MN)
- Table 5 Global Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Acetaminophen (2021-2030) ($MN)
- Table 6 Global Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Oral Contraceptives (2021-2030) ($MN)
- Table 7 Global Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Other Types (2021-2030) ($MN)
- Table 8 Global Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By End User (2021-2030) ($MN)
- Table 9 Global Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
- Table 10 Global Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 11 Global Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Research Institutes (2021-2030) ($MN)
- Table 12 Global Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Specialty Clinics and Rehab Centers (2021-2030) ($MN)
- Table 13 Global Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 14 North America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Country (2021-2030) ($MN)
- Table 15 North America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Type (2021-2030) ($MN)
- Table 16 North America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Breast Biopsy (2021-2030) ($MN)
- Table 17 North America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Nonsteroidal Anti Inflammatory Drugs (2021-2030) ($MN)
- Table 18 North America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Acetaminophen (2021-2030) ($MN)
- Table 19 North America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Oral Contraceptives (2021-2030) ($MN)
- Table 20 North America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Other Types (2021-2030) ($MN)
- Table 21 North America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By End User (2021-2030) ($MN)
- Table 22 North America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
- Table 23 North America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 24 North America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Research Institutes (2021-2030) ($MN)
- Table 25 North America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Specialty Clinics and Rehab Centers (2021-2030) ($MN)
- Table 26 North America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 27 Europe Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Country (2021-2030) ($MN)
- Table 28 Europe Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Type (2021-2030) ($MN)
- Table 29 Europe Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Breast Biopsy (2021-2030) ($MN)
- Table 30 Europe Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Nonsteroidal Anti Inflammatory Drugs (2021-2030) ($MN)
- Table 31 Europe Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Acetaminophen (2021-2030) ($MN)
- Table 32 Europe Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Oral Contraceptives (2021-2030) ($MN)
- Table 33 Europe Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Other Types (2021-2030) ($MN)
- Table 34 Europe Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By End User (2021-2030) ($MN)
- Table 35 Europe Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
- Table 36 Europe Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 37 Europe Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Research Institutes (2021-2030) ($MN)
- Table 38 Europe Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Specialty Clinics and Rehab Centers (2021-2030) ($MN)
- Table 39 Europe Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 40 Asia Pacific Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Country (2021-2030) ($MN)
- Table 41 Asia Pacific Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Type (2021-2030) ($MN)
- Table 42 Asia Pacific Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Breast Biopsy (2021-2030) ($MN)
- Table 43 Asia Pacific Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Nonsteroidal Anti Inflammatory Drugs (2021-2030) ($MN)
- Table 44 Asia Pacific Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Acetaminophen (2021-2030) ($MN)
- Table 45 Asia Pacific Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Oral Contraceptives (2021-2030) ($MN)
- Table 46 Asia Pacific Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Other Types (2021-2030) ($MN)
- Table 47 Asia Pacific Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By End User (2021-2030) ($MN)
- Table 48 Asia Pacific Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
- Table 49 Asia Pacific Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 50 Asia Pacific Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Research Institutes (2021-2030) ($MN)
- Table 51 Asia Pacific Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Specialty Clinics and Rehab Centers (2021-2030) ($MN)
- Table 52 Asia Pacific Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 53 South America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Country (2021-2030) ($MN)
- Table 54 South America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Type (2021-2030) ($MN)
- Table 55 South America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Breast Biopsy (2021-2030) ($MN)
- Table 56 South America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Nonsteroidal Anti Inflammatory Drugs (2021-2030) ($MN)
- Table 57 South America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Acetaminophen (2021-2030) ($MN)
- Table 58 South America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Oral Contraceptives (2021-2030) ($MN)
- Table 59 South America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Other Types (2021-2030) ($MN)
- Table 60 South America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By End User (2021-2030) ($MN)
- Table 61 South America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
- Table 62 South America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 63 South America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Research Institutes (2021-2030) ($MN)
- Table 64 South America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Specialty Clinics and Rehab Centers (2021-2030) ($MN)
- Table 65 South America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 66 Middle East & Africa Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Country (2021-2030) ($MN)
- Table 67 Middle East & Africa Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Type (2021-2030) ($MN)
- Table 68 Middle East & Africa Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Breast Biopsy (2021-2030) ($MN)
- Table 69 Middle East & Africa Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Nonsteroidal Anti Inflammatory Drugs (2021-2030) ($MN)
- Table 70 Middle East & Africa Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Acetaminophen (2021-2030) ($MN)
- Table 71 Middle East & Africa Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Oral Contraceptives (2021-2030) ($MN)
- Table 72 Middle East & Africa Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Other Types (2021-2030) ($MN)
- Table 73 Middle East & Africa Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By End User (2021-2030) ($MN)
- Table 74 Middle East & Africa Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
- Table 75 Middle East & Africa Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 76 Middle East & Africa Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Research Institutes (2021-2030) ($MN)
- Table 77 Middle East & Africa Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Specialty Clinics and Rehab Centers (2021-2030) ($MN)
- Table 78 Middle East & Africa Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
